Full Press Release Details
Immutep Receives A$ 3.6 Million R&D Tax Incentive from French Government
SYDNEY, AUSTRALIA 29 May 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the
Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a 2,173,454 (~ A$3,630,000) research and development (R&D) tax incentive
payment in cash from the French Government under its Cr dit d Imp t Recherche scheme (CIR).
Recherche (CIR), meaning Research Tax Credit , is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
Immutep qualifies to receive CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory at
Ch tenay-Malabry in southwestern Paris.
The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha
and the preclinical development of IMP761.
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Immutep s current lead product
candidate is eftilagimod alpha ( efti or IMP321 ), a soluble LAG-3 protein (LAG-3Ig) based on the LAG-3
immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov
identifier NCT02614833); a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) referred to as
TACTI-002 to evaluate a combination of efti with KEYTRUDA (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier
NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. referred to as INSIGHT-004 to evaluate a combination of efti with avelumab
(clinicaltrials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869).
Level 12, 95 Pitt Street, Sydney NSW 2000
Additional LAG-3 products, including antibodies, for immune response
modulation in autoimmunity and cancer are being developed by Immutep s large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
This announcement was authorised for release by the Chief Executive Officer of Immutep Limited.
Further information can be found on the Company s website www.immutep.com or by contacting:
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; garth@lifesciadvisors.com
Level 12, 95 Pitt Street, Sydney NSW 2000